Home » Newsletters » BioWorld Science

BioWorld Science

May 22, 2014

View Archived Issues

Scientists at University of North Carolina design novel Mer inhibitors

Vertex designs selective HSP inhibitors for neurodegenerative disorders

Synthetic MTDL as a novel therapeutic for ischemic stroke

Viral-induced overexpression of ITGA7 presented as a therapeutic approach for DMD

GSK's fluticasone plus umeclidinium combination safe in phase I trial

Bioequivalence study begins for Elite Pharmaceuticals' third opioid abuse deterrent drug

Clinical trial results presented for liraglutide for weight management and diabetes

Pharmaleads patents new mixed NEP/AP-N inhibitors

Novel dsRNA molecules divulged by PhaseRx

Genprex begins phase II trial of Oncoprex in lung cancer

Ceapro licenses dry powder formulation technology from University of Alberta

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical obtains Chinese clinical trial clearance

Terumo BCT and Kaneka collaborate on therapeutic apheresis and columns for LDL reduction

Cardio3 BioSciences enters agreement with ViroMed for use of C-Cathez in VM-202-CAD development

Proteo Biotech agrees to financing deal for orphan drug development

UCB invests in collaboration partner Beryllium

Sirona Biochem discloses cell protection agent

Japan Tobacco discloses new ROR-gamma antagonists

New BTK inhibitors patented by Roche

Japanese orphan drug designation for Edison's EPI-743 in Leigh syndrome

Summit reports results from phase Ib study of SMT-C1100 in pediatric DMD patients

GlycoMimetics receives payment from Pfizer in connection with phase III trial

aTyr Pharma completes first phase I study of Resokine

Baxter provides regulatory update on HyQvia

Antibe Therapeutics submits CTA for ATB-346

BioAlliance and Topotarget merge to form Onxeo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...